Sonnet BioTherapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity (Deficit) (Details Narrative)

Stockholders’ Equity (Deficit) (Details Narrative) - USD ($)					3 Months Ended			6 Months Ended
	May 02, 2024	Oct. 26, 2023	Feb. 10, 2023	Aug. 15, 2022	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2024	Mar. 31, 2023
Subsidiary, Sale of Stock [Line Items]
Proceeds from sale of common stock			$ 13,600,000					$ 3,838,870	$ 19,209,252
Gross proceeds from sale agreement			$ 15,000,000.0
Offering price for common stock					$ 3,916,943	$ 14,515,968	$ 4,452,012
Proceeds from warrant exercises								$ 56,000
2022 Sales Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Offering price for common stock				$ 7,800,000
2022 Sales Agreement [Member] \| BTIG, LLC [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds from sale of common stock									$ 5,500,000
Sale of stock, shares									136,702
Gross proceeds from sale agreement									$ 5,700,000
Offering price for common stock				$ 25,000,000.0
Underwriter Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Purchase of warrants			44,190
Exercisable price			$ 29.70
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Sales price			23.76
Exercisable price			23.76
Sale of common stock, net of issuance costs, shares	622,168				1,306,250	557,083	109,841
Offering price for common stock	$ 25,000,000.0				$ 131	$ 56	$ 11
Net share settlement of warrants, shares					14,362	10,521	137
Prefunded Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Sales price			23.7578
Exercisable price per share			$ 0.0022
Common Stock Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of common stock, net of issuance costs, shares								14,362	10,658
Net share settlement of warrants, shares								28,724	21,180
Number of warrant exercised								35,000
Proceeds from warrant exercises								$ 100,000
Number of warrant expired									332
Investors [Member] \| Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Purchase of warrants			1,262,618
Sale of common stock, net of issuance costs, shares			530,222
Investors [Member] \| Prefunded Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Purchase of warrants			101,090
Holder [Member] \| Common Stock Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Forfeited warrants, shares								34,458
October Offering [Member] \| Prefunded Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Purchase of warrants								1,537,500
Exercisable price								$ 0.0001
October Offering [Member] \| Underwriters [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds from sale of common stock		$ 3,900,000
Purchase of warrants		85,312
Exercisable price		$ 2.00
October Offering [Member] \| Underwriters [Member] \| Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock, shares		1,306,250
Exercisable price		$ 0.0001
October Offering [Member] \| Underwriters [Member] \| Prefunded Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Purchase of warrants		1,537,500
Sales price		$ 1.5999
October Offering [Member] \| Underwriters [Member] \| Common Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Purchase of warrants		5,687,500
Sales price		$ 1.60
Exercisable price		$ 1.60